A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption

Nicotine and Tobacco Research

Volumn 1, Issue SUPPL. 2, 1999, Pages

  Tyndale, Rachel F ^a,b,c   Pianezza, Michael L ^b   Sellers, Edward M ^b,c,d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; CYTOCHROME P 450 ENZYME SYSTEM; CYTOCHROME P450; MIXED FUNCTION OXIDASE; NICOTINE;

ALLELE; FEMALE; GENETICS; HUMAN; IATROGENIC DISEASE; MALE; METABOLISM; MUTATION; NEOPLASM; REVIEW; SEX DIFFERENCE; SMOKING; TOBACCO DEPENDENCE;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMAN; MALE; MIXED FUNCTION OXYGENASES; MUTATION; NEOPLASMS; NICOTINE; SEX FACTORS; SMOKING; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOBACCO USE DISORDER;

EID: 0033301675     PISSN: 14622203     EISSN: None     Source Type: Journal    
DOI: 10.1080/14622299050011831     Document Type: Article

References (25)

1. Benowitz NL, Jacob P. 1984. Daily intake of nicotine during cigarette smoking. Clinical Pharmacology Therapeutics 35(4):499-504.
2. Benowitz NL, Jacob P 3rd, Fong I, Gupta. 1994. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. Journal of Pharmacology and Experimental Therapeutics 268(1):296-303.
3. Crespi CL, Penman BW, Leakey JA, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL et al. 1990. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11(8):1293-1300.
4. Fernandez-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang J, Evans WE, Idle JR, Gonzalez FJ. 1995. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. American Journal of Human Genetics 57:651-660.
5. Groeger AM, Mueller MR, Odocha O, Dekan G, Salat A, Rothy W, Esposito V, Caputi M, Wolner E, Kaiser HE. 1997. Ethnic variations in lung cancer. Anticancer Research 17(4A):2849-2857.
6. Hatsukami D, Skoog K, Allen S, Bliss R. 1995. Gender and the effects of different doses of nicotine gum on tobacco withdrawal symptoms. Experimental and Clinical Psychopharmology 3:163-173.
7. Henningfield JE, Miyasato K, Jasinski DR. 1985. Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. Journal of Pharmacology and Experimental Therapeutics 234(1):1-12.
8. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. 1994. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug and Alcohol Dependence 34(3):211-216.
9. Law MR, Morris JK, Watt HC, Wald NJ. 1997. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. British Journal of Cancer 75:1690-1693.
10. Messina ES, Tyndale RF, Sellers EM. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 282(3):1608-1614
11. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y. 1996. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metabolism and Disposition 11:1212-1217.
12. Nowak M, EM Sellers, RF Tyndale. 1998. Canadian native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clinical Pharmacology and Therapeutics in press.
13. Pearce R, Greenway D, Parkinson A. 1992. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Archives of Biochemistry and Biophysics 298(1):211-225.
14. Perkins KA. 1996. Sex differences in nicotine versus nonnicotine reinforcement as determinants of tobacco smoking. Experimental and Clinical Psychopharmacology 4:166-177.
15. Pianezza M, Sellers EM, Tyndale RF. 1998. A common genetic defect in nicotine metabolism decreases smoking. Nature 393(6687):750.
16. Pomerleau OF, Fertig JB, Shanahan SO. 1993. Nicotine dependence in cigarette smoking: An empirically-based, multivariate model. Pharmacological Biochemical Behaviour 19:291-299.
17. Rautio A, Gullsten H, Pelkonen O, Raunio H. 1996. Abstract: International Symposium on Microsomes and Drug Oxidation, 146.
18. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. 1992. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 2(5):227-233.
19. Russel, M.S.H. 1987. In: Martin WR, Vauhon GR, Iwamoto ET, David L, eds. Advances in Behavioural Biology. New York: Plenum Press, pp. 25-50.
20. Sellers EM, Kaplan HL, Romach MK, Tyndale RF. 1999. Inhibition of CYP2A6 decreases smoking. American Society for Clinical Pharmacology and Therapeutics, Abstract.
21. True WR, Heath AC, Scherrer JF, Waterman B, Goldberg J, Lin N, Eisen SA, Lyons MJ, Tsuang, MT. 1997. Genetic and environmental contributions to smoking. Addiction 92(10):1277-1287.
22. Tyndale RF, Li Y, Kaplan HL, Sellers EM 1999. Inhibition of nicotine's metabolism: A potential treatment for tobacco dependence. American Society for Clinical Pharmacology and Therapeutics, 1999 Abstract.
23. Woodward M, Tunstall-Pedoe H. 1993. Self-titration of nicotine: evidence from the Scottish Heart Health Study. Addiction 88:821-830.
24. Yamano S, Tatsuno J, Gonzalez FJ. 1990. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29(5):1322-1329.
25. Yokoi T, Kamataki T. 1998. Genetic polymorphism of drug metabolizing enzymes: New mutations in the CYP2D6 and CYP2A6 genes in Japanese. Pharmaceutical Research 4:517-524.